Moreover, the treatment of IL-22RA1+MM cells with IL-22 increases both cell growth through p38 mitogen activated protein kinase (MAPK)activation and resistance to drug-induced cell death through up-regulation of myeloid leukemia 1 (Mcl-1) expression and inhibition of drug-induced caspase-3 activation (46). This evidence concerns the gene IL22 and Miyoshi myopathy.